
CLAIMS





1. A compound of Formula (I):




(I)

or stereoisomers, tautomers, or salts thereof, wherein:


R is:




or

.


2. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:


.

3. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



.

4. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



.

5. The compound according to claim 1, or stereoisomers, tautomers, or salts thereof, wherein said compound is:



.

6. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

7. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 6, for use in therapy.

8. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 6, for use in the treatment of cancer.

9. The compound or the pharmaceutical composition for use according to claim 8, wherein said cancer is selected from cancer of the colon, gastric, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

10. The compound or the pharmaceutical composition for use according to claim 8, wherein a second agent is to be further administered to said patient, prior to,

simultaneously with or after administration of said compound, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine.

11. The compound, or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 6, for use in the treatment of a disease by decreasing Ikaros, Helios, Aiolos and Eos protein levels.

12. The compound or the pharmaceutical composition for use according to claim 11, wherein:

a) said Ikaros protein is the amino acid sequence encoded by SEQ ID NOs: 1, 2, 3, 4, 5, or 6;

b) said Helios protein is the amino acid sequence encoded by SEQ ID NOs: 7,8, 9, 10, or 11;

c) said Aiolos protein is the amino acid sequence encoded by SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, or 19; and

d) said Eos protein is the amino acid sequence encoded by SEQ ID NOs: 20 or 21.

13. The compound or the pharmaceutical composition for use according to claim 12, wherein

a) said Ikaros protein level is decreased by at least 30 %;

b) said Helios protein level is decreased by at least 50 %;

c) said Aiolos protein level is decreased by at least 10 %; and

d) said Eos protein level is decreased by at least 30 %.

14. The compound or the pharmaceutical composition for use according to claim 13, wherein a second agent is to be further administered to said patient, prior to, simultaneously with or after administration of said compound, wherein said second agent is selected from an antagonist of PD1/PD-L1 axis, an antagonist of CTLA4, a chemotherapeutic agent, radiation, or an anti-tumor vaccine.

15. An *in vitro* method of decreasing Ikaros, Helios, Aiolos, and Eos protein levels in cells comprising contacting said cells with a compound according to any one of claims 1 to 5, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.